ASEPTIC PROCESSING: TWO - Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing - page 267

38. EudraLex The Rules Governing Medicinal Products in the European Union, Vol-
ume 4 EU Guidelines to Good Manufacturing Practice Medicinal Products for
Human and Veterinary Use Annex 1 Manufacture of Sterile Medicinal Prod-
ucts. Available at http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents
/eudralex/vol-4/index_en.htm#h2-annexes. 2008.
39. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacte-
rial community variation in human body habitats across space and time. Science
2009;326:1694-1697.
40. Anderson T-H. Microbial eco-physiological indicators to asses soil quality. Agric
Ecosyst Environ 2003;98:285-293.
41. Torsvik V, Golsor J, Daae F. High diversity in DNA of soil bacteria. Appl Environ
Microbiol 1990;56:782-787.
42. Atlas RM, Bartha R. Microbial Ecology: Fundamentals and Applications. Redwood
(CA): Benjamin/Cummings; 1998.
43. Gao Z, Tseng C-H, Pei Z, Blaser MJ. Molecular analysis of human forearm superficial
skin bacterial biota. Proc Nat Acad Sci 2007;40(8):2927-2932.
44. Wade W. Unculturable bacteria-the uncharacterized organisms that cause oral infec-
tions. J R Soc Med 2002;95:81-83.
45. La Duc MD. Isolation and characterization of bacteria capable of tolerating the
extreme conditions of clean room environments. Appl Environ Microbiol 2007;73(8):
2600-2611.
46. De Kimpe SJ, Kengatharan M, Thiemermann C, Vane R. The cell wall compo-
nents of peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in
synergy to cause shock and multiple organ failure. Proc Nat Acad Sci USA 1995;92:
10359-10363.
47. Wray GM, Foster SJ, Hinds CJ, Thiemermann C. A cell wall component from
pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergizes
with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide
production, shock and multiple organ injury/dysfunction in the rat. Shock 2001;15:
135-142.
48. Eaton T. Microbial risk assessment for aseptically prepared products. Am Pharm Rev
2005;8(5):46-51.
49. Tidswell EC, Bellinger M, McCullough D, Allexander A. Consecutive replicate con-
tact plate sampling assists investigative characterization of surface-borne bioburden.
Eur J Parenter Pharm Sci 2005;10(4):93-96.
50. Sutton S. Is real-time release through PAT compatible with the Ideal of “Science-
Based Regulation?”. Pharm Technol 2007 February. 2, 2007, www.pharmtech.com.
51. Whyte W. Collection efficiency of microbial methods used to monitor cleanrooms.
Eur J Parenter Pharm Sci 2005;10(2):43-50.
52. Anderson T-H. Microbial eco-physiological indicators to asses soil quality. Agric
Ecosyst Environ 2003;98:285-293.
53. Torsvik VG. High diversity in DNA of soil bacteria. Appl Environ Microbiol
1990;56:782-787.
54. Errington J. Determination of cell fate in Bacillus subtilis . Trends Genet 1996;12:
31-34.